Targeted therapy for lung adenocarcinoma is like a “precision-guided” missile nowadays, which can strike precisely after targeting the target, the “targets” are EGFR, T790M, ALK, ROS1, PD-L1, etc. Therefore, the following targeted therapy regimens are available. For EGFR mutation-positive lung adenocarcinoma, the first-line EGFR-targeted drugs are erlotinib, gefitinib, erlotinib and afatinib, which are more advantageous than the first-line platinum-containing two-drug chemotherapy regimens and have lower toxic effects, and can also be used for second- or third-line oral therapy when chemotherapy is ineffective. second-line targeted agent, oseltinib. For ALK and ROS1 positive patients, crizotinib therapy is an option. For patients with advanced lung adenocarcinoma, if patients do not have hemoptysis and brain metastasis, combination of anti-tumor vascular targeting drugs such as bevacizumab on top of chemotherapy can be considered. for PD-L1 positive patients, anti-PD-1/PD-L1 drugs such as Pembro (pembrolumab), Nivo (nabumab) and atezumab can be used.